Pursuant to regulation 24(A) of SEBI Listing Regulations, the Annual Secretarial Compliance Report for the year ended March 31, 2025 is enclosed herewith.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories has submitted its Annual Secretarial Compliance Report for FY 2024-25, as required under SEBI Listing Regulations. A Practising Company Secretary (M. Alagar & Associates) reviewed the company's compliance with SEBI regulations, circulars, and guidelines for the year. The report confirms overall compliance with all examined areas, including secretarial standards, policies, website disclosures, related-party transactions, insider trading rules, and subsidiary disclosures. One instance of non-compliance was flagged: a delay in intimating stock exchanges (BSE and NSE) about the outcome of an investor/analyst meeting held on August 30, 2024, under Regulation 30 of SEBI LODR. No fine was imposed, though BSE issued a caution letter, and the company states it has taken steps to prevent future delays. No actions were taken by SEBI or stock exchanges against the company during the period.
This is a routine annual compliance filing with one minor procedural lapse that carried no financial penalty. For shareholders, it signals strong overall regulatory compliance with a small disclosure-timeliness hiccup already addressed by management — unlikely to move the stock price.